Business Context and Reporting Period
This Form 8-K reports on the 2016 Annual Meeting of Stockholders held on June 15, 2016. The registrant is Signal Genetics, Inc., a Delaware corporation. Note: The request metadata references "Viridian Therapeutics, Inc.," but the filing text explicitly identifies the company as Signal Genetics, Inc.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and stockholder votes. It does not contain financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Corporate Actions
Three proposals were submitted to and approved by stockholders:
- Director Elections: Five directors were elected to one-year terms: Bennett S. LeBow, Samuel D. Riccitelli, David A. Gonyer, Douglas A. Schuling, and Robin L. Smith, M.D.
- Auditor Ratification: Stockholders ratified the selection of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016.
- Reverse Stock Split: Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split. The Board of Directors will determine the specific ratio within a range of 1-for-2 to 1-for-20.
Voting Results Summary
| Proposal | For | Against | Abstained |
|---|---|---|---|
| Election of Directors (Aggregate) | 18,472,142 | 4,365,777 | 397,436 |
| Ratification of Auditor | 6,893,644 | 1,238,328 | 145,177 |
| Reverse Stock Split | 6,470,138 | 1,721,729 | 85,282 |
Guidance, Outlook, and Risks
The filing does not provide management commentary on financial guidance, outlook, or specific risks beyond the standard disclosure that the reverse stock split ratio is to be determined by the Board. No unusual items or contingencies are disclosed in this report.
Investor Verification Checklist
- Verify the specific reverse stock split ratio once announced by the Board of Directors (range: 1-for-2 to 1-for-20).
- Confirm the effective date of the reverse stock split and any resulting changes to share price and volume.
- Review the Definitive Proxy Statement (Schedule 14A) filed on May 9, 2016, for detailed biographies of the newly elected directors and further context on the auditor ratification.
- Monitor subsequent filings for the implementation of the stock split and any impact on the company's listing status.